Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Prostatic Neoplasms | 11 | 2026 | 986 | 3.330 |
Why?
|
| Prostatic Neoplasms, Castration-Resistant | 6 | 2025 | 54 | 2.440 |
Why?
|
| Recombinational DNA Repair | 3 | 2025 | 19 | 1.940 |
Why?
|
| Poly(ADP-ribose) Polymerase Inhibitors | 4 | 2025 | 137 | 1.760 |
Why?
|
| Neoplastic Syndromes, Hereditary | 3 | 2022 | 47 | 1.010 |
Why?
|
| Androgen Antagonists | 2 | 2023 | 91 | 0.810 |
Why?
|
| Biomarkers, Tumor | 5 | 2025 | 1339 | 0.790 |
Why?
|
| Carcinoma, Neuroendocrine | 1 | 2023 | 38 | 0.730 |
Why?
|
| Aldo-Keto Reductase Family 1 Member C3 | 1 | 2021 | 1 | 0.670 |
Why?
|
| Prostatectomy | 1 | 2021 | 94 | 0.640 |
Why?
|
| Receptors, Androgen | 2 | 2024 | 149 | 0.610 |
Why?
|
| Antineoplastic Agents, Hormonal | 1 | 2021 | 196 | 0.590 |
Why?
|
| Mutation | 8 | 2025 | 4130 | 0.580 |
Why?
|
| Kidney Neoplasms | 2 | 2024 | 421 | 0.580 |
Why?
|
| Pregnancy Complications, Neoplastic | 1 | 2019 | 64 | 0.570 |
Why?
|
| Wilms Tumor | 1 | 2019 | 90 | 0.550 |
Why?
|
| Epididymis | 1 | 2017 | 14 | 0.530 |
Why?
|
| Neoadjuvant Therapy | 1 | 2021 | 474 | 0.520 |
Why?
|
| Testicular Neoplasms | 1 | 2017 | 111 | 0.470 |
Why?
|
| Dipeptides | 2 | 2025 | 56 | 0.420 |
Why?
|
| Molecular Targeted Therapy | 1 | 2016 | 444 | 0.380 |
Why?
|
| Antineoplastic Agents | 3 | 2024 | 2231 | 0.370 |
Why?
|
| Androgens | 2 | 2025 | 181 | 0.360 |
Why?
|
| Adenocarcinoma | 1 | 2017 | 928 | 0.310 |
Why?
|
| Male | 17 | 2026 | 73950 | 0.290 |
Why?
|
| Colorectal Neoplasms | 3 | 2022 | 876 | 0.280 |
Why?
|
| Lutetium | 2 | 2025 | 5 | 0.260 |
Why?
|
| Brain Neoplasms | 3 | 2022 | 1338 | 0.260 |
Why?
|
| Retrospective Studies | 8 | 2025 | 17560 | 0.260 |
Why?
|
| Aged | 9 | 2025 | 26514 | 0.240 |
Why?
|
| Humans | 20 | 2026 | 147293 | 0.230 |
Why?
|
| Neoplasms | 1 | 2021 | 2946 | 0.230 |
Why?
|
| BRCA2 Protein | 1 | 2025 | 68 | 0.220 |
Why?
|
| BRCA1 Protein | 1 | 2025 | 83 | 0.220 |
Why?
|
| Lung Neoplasms | 1 | 2017 | 2679 | 0.200 |
Why?
|
| Precision Medicine | 3 | 2024 | 464 | 0.200 |
Why?
|
| Circulating Tumor DNA | 1 | 2024 | 50 | 0.200 |
Why?
|
| Aged, 80 and over | 4 | 2025 | 8430 | 0.190 |
Why?
|
| Wnt Signaling Pathway | 1 | 2024 | 212 | 0.180 |
Why?
|
| Neoplasm Metastasis | 2 | 2026 | 695 | 0.180 |
Why?
|
| Quantitative Trait Loci | 1 | 2024 | 389 | 0.170 |
Why?
|
| Prostate | 1 | 2023 | 160 | 0.170 |
Why?
|
| Carcinoma, Renal Cell | 1 | 2024 | 233 | 0.170 |
Why?
|
| DNA Damage | 1 | 2024 | 440 | 0.170 |
Why?
|
| Thiohydantoins | 1 | 2021 | 5 | 0.170 |
Why?
|
| Androgen Receptor Antagonists | 2 | 2024 | 35 | 0.170 |
Why?
|
| Abiraterone Acetate | 1 | 2021 | 15 | 0.170 |
Why?
|
| Middle Aged | 7 | 2025 | 36821 | 0.150 |
Why?
|
| Programmed Cell Death 1 Receptor | 1 | 2020 | 268 | 0.130 |
Why?
|
| Cystadenoma, Papillary | 1 | 2017 | 1 | 0.130 |
Why?
|
| Inguinal Canal | 1 | 2017 | 11 | 0.130 |
Why?
|
| Scrotum | 1 | 2017 | 25 | 0.130 |
Why?
|
| Orchiectomy | 1 | 2017 | 72 | 0.130 |
Why?
|
| Genome-Wide Association Study | 1 | 2024 | 1496 | 0.130 |
Why?
|
| Survival Analysis | 1 | 2020 | 1386 | 0.120 |
Why?
|
| Treatment Outcome | 3 | 2025 | 11947 | 0.120 |
Why?
|
| Immunotherapy | 1 | 2021 | 672 | 0.120 |
Why?
|
| Polymorphism, Single Nucleotide | 1 | 2024 | 2223 | 0.120 |
Why?
|
| Combined Modality Therapy | 1 | 2019 | 1281 | 0.120 |
Why?
|
| Androstenes | 1 | 2016 | 16 | 0.120 |
Why?
|
| Phenylthiohydantoin | 1 | 2016 | 44 | 0.120 |
Why?
|
| Genetic Predisposition to Disease | 1 | 2024 | 2458 | 0.110 |
Why?
|
| Benzamides | 1 | 2016 | 227 | 0.110 |
Why?
|
| Nitriles | 1 | 2016 | 211 | 0.110 |
Why?
|
| Follow-Up Studies | 2 | 2024 | 5476 | 0.100 |
Why?
|
| Prostate-Specific Antigen | 2 | 2025 | 162 | 0.100 |
Why?
|
| Risk Assessment | 1 | 2023 | 3784 | 0.100 |
Why?
|
| Prognosis | 3 | 2026 | 4383 | 0.090 |
Why?
|
| Drug Resistance, Neoplasm | 1 | 2016 | 889 | 0.080 |
Why?
|
| Genomics | 2 | 2025 | 839 | 0.070 |
Why?
|
| Adult | 3 | 2024 | 41405 | 0.060 |
Why?
|
| Pregnancy | 1 | 2019 | 7274 | 0.060 |
Why?
|
| Microsatellite Instability | 1 | 2025 | 57 | 0.050 |
Why?
|
| Retinoblastoma Binding Proteins | 1 | 2024 | 10 | 0.050 |
Why?
|
| Adenomatous Polyposis Coli Protein | 1 | 2024 | 21 | 0.050 |
Why?
|
| Heterocyclic Compounds, 1-Ring | 1 | 2024 | 7 | 0.050 |
Why?
|
| Von Hippel-Lindau Tumor Suppressor Protein | 1 | 2024 | 19 | 0.050 |
Why?
|
| Glutamate Carboxypeptidase II | 1 | 2024 | 8 | 0.050 |
Why?
|
| ROC Curve | 1 | 2026 | 626 | 0.050 |
Why?
|
| Antigens, Surface | 1 | 2024 | 155 | 0.050 |
Why?
|
| Epithelial-Mesenchymal Transition | 1 | 2025 | 222 | 0.050 |
Why?
|
| Ubiquitin-Protein Ligases | 1 | 2024 | 199 | 0.050 |
Why?
|
| Signal Transduction | 1 | 2016 | 5272 | 0.040 |
Why?
|
| beta Catenin | 1 | 2024 | 254 | 0.040 |
Why?
|
| High-Throughput Nucleotide Sequencing | 1 | 2024 | 539 | 0.040 |
Why?
|
| Gene Expression Regulation, Neoplastic | 1 | 2025 | 1457 | 0.030 |
Why?
|
| Medical Oncology | 1 | 2021 | 344 | 0.030 |
Why?
|
| Case-Control Studies | 1 | 2024 | 3660 | 0.030 |
Why?
|
| Disease Progression | 1 | 2024 | 2890 | 0.030 |
Why?
|
| Cohort Studies | 1 | 2024 | 6099 | 0.020 |
Why?
|
| Female | 1 | 2019 | 80076 | 0.020 |
Why?
|
| Prospective Studies | 1 | 2021 | 8164 | 0.020 |
Why?
|